422 related articles for article (PubMed ID: 31473172)
21. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
[TBL] [Abstract][Full Text] [Related]
23. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
24. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
25. Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema.
Rahimy E; Baker K; Thompson D; Saroj N;
Ophthalmic Surg Lasers Imaging Retina; 2020 Apr; 51(4):226-234. PubMed ID: 32348539
[TBL] [Abstract][Full Text] [Related]
26. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
28. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
[TBL] [Abstract][Full Text] [Related]
30. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
[TBL] [Abstract][Full Text] [Related]
31. Retinal Reflectivity Measurement for Cone Impairment Estimation and Visual Assessment After Diabetic Macular Edema Resolution (RECOVER-DME).
Guyon B; Elphege E; Flores M; Gauthier AS; Delbosc B; Saleh M
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6241-6247. PubMed ID: 29228252
[TBL] [Abstract][Full Text] [Related]
32. Correlation between Deep Capillary Plexus Perfusion and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment.
Moon BG; Um T; Lee J; Yoon YH
Ophthalmol Retina; 2018 Mar; 2(3):235-243. PubMed ID: 31047592
[TBL] [Abstract][Full Text] [Related]
33. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
35. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
36. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept and navigated versus conventional laser in diabetic macular oedema: a 12-month randomized clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):347-352. PubMed ID: 31602811
[TBL] [Abstract][Full Text] [Related]
38. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
[TBL] [Abstract][Full Text] [Related]
39. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.
Lee H; Kang KE; Chung H; Kim HC
Jpn J Ophthalmol; 2019 May; 63(3):234-242. PubMed ID: 30783942
[TBL] [Abstract][Full Text] [Related]
40. Prevention of Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery: The PROMISE Trial.
Song W; Conti TF; Gans R; Conti FF; Silva FQ; Saroj N; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):170-178. PubMed ID: 32211907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
